NCT05625737View on ClinicalTrials.gov

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

September 30, 2025

Conditions
Stomach Neoplasms
Interventions
DRUG

Fruquintinib

Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.

DRUG

Sintilimab

Sintilimab will be administrated as 200mg once every 3 weeks.

Trial Locations (1)

430030

Wuhan Union Hospital, China, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER